Business Wire (Thu, 4:30PM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
798 people get CBST articles and Market Currents by email alert.
Get email alerts on CBST »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Business Wire (Sun, 7:00AM)
-
-
-
-
-
Business Wire (May 8, 2013)
-
Business Wire (May 7, 2013)
-
-
-
Business Wire (Apr 18, 2013)
-
Business Wire (Apr 11, 2013)
-
Business Wire (Apr 9, 2013)
-
-
-
-
Business Wire (Mar 11, 2013)
-
-
Business Wire (Mar 4, 2013)
To learn more about Seeking Alpha Pro, click here.
-
-
-
Cubist Pharmaceuticals: Earnings PreviewZacks Investment Research • Tue, Jan 17, 2012 -
Cubist's Adolor Acquisition Aligns Well With Its Own Skill SetEP Vantage • Thu, Oct 27, 2011 -
-
-
A Pre-Earnings Look at Cubist PharmaVantage Point Investor • Mon, Jul 11, 2011 -
Cubist's Q4 Preliminary Sales DownZacks Investment Research • Thu, Jan 13, 2011
-
-
-
-
A Closer Look at Cubist PharmaR. Scott Raynovich • Thu, Jan 14, 2010
-
-
-
Cubist Pharmaceuticals: Betting On BiotechMichael Michaud • Tue, Jan 8, 2008 -
Cubist Pharma Focuses On Abandoned Antibiotic MarketFaisal Laljee • Tue, Feb 20, 2007
-
Cubist Pharmaceuticals, Inc. Q1 2010 Earnings Call TranscriptThu, Apr 15, 2010
-
Cubist Pharmaceuticals, Inc. Q4 2009 Earnings Call TranscriptThu, Jan 21, 2010
-
Cubist Pharmaceuticals, Inc. Q3 2009 Earnings Call TranscriptFri, Oct 16, 2009
-
Cubist Pharmaceuticals, Inc. Q1 2009 Earnings Call TranscriptTue, Apr 21, 2009
-
Cubist Pharmaceuticals Inc. Q4 2008 Earnings Call TranscriptFri, Jan 23, 2009
-
Cubist Pharmaceuticals Inc. Q3 2008 Earnings Call TranscriptThu, Oct 16, 2008
-
Cubist Pharmaceuticals, Inc. Q2 2008 Earnings Call TranscriptThu, Jul 17, 2008
-
Cubist Pharmaceuticals Inc. Q1 2008 Earnings Call TranscriptThu, Apr 17, 2008
-
Cubist Pharmaceuticals Q4 2007 Earnings Call TranscriptWed, Jan 23, 2008
-
Cubist Pharmaceuticals Q3 Earnings Call TranscriptWed, Oct 17, 2007
-
Business Wire (Thu, 4:30PM)
-
Business Wire (Sun, 7:00AM)
-
Business Wire (May 8, 2013)
-
Business Wire (May 7, 2013)
-
at CNBC.com (Apr 23, 2013)
-
Business Wire (Apr 18, 2013)
-
Business Wire (Apr 11, 2013)
-
Business Wire (Apr 9, 2013)
-
Business Wire (Mar 11, 2013)
-
at CNBC.com (Mar 7, 2013)
-
Business Wire (Mar 4, 2013)
-
Business Wire (Feb 28, 2013)
-
Business Wire (Feb 27, 2013)
-
Business Wire (Feb 25, 2013)
-
Business Wire (Jan 29, 2013)
-
at MarketWatch.com (Jan 23, 2013)
-
Business Wire (Jan 23, 2013)
-
Business Wire (Jan 8, 2013)
-
Business Wire (Jan 7, 2013)
-
Business Wire (Dec 21, 2012)
CBST vs. ETF Alternatives
Company Description
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. Such products are used, or are being developed to be used, primarily in hospitals but... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, May 24, 12:06 PM Cubist Pharmaceuticals (CBST -1.5%) slips on a downgrade to Neutral on valuation at Janney Capital. Despite the downgrade - not to mention a 36% runup in the shares since last November - the firm raises its price target on the stock by another 10% to $55 from $50. Separately, CBST's CEO Mike Bonney is scheduled to present at Jefferies 2013 Global Healthcare Conference on Monday, June 3, to discuss it's pipeline, financial outlook, and recentdevelopments. Tune into the live presentation here: (Webcast) Comment! [Healthcare, On the Move]
- Friday, May 24, 8:18 AM Janney Montgomery Scott cuts Cubist Pharmaceuticals (CBST) to Neutral and takes its price target to $50 from $55, bringing its rating and PT largely in line with those of Cantor's Irina Rivkind who upgraded the stock to Hold from Sell (price target $49) on Tuesday. Comment! [Healthcare]
- Tuesday, May 21, 9:46 AM Cantor Fitzgerald's Irina Rivkind upgrades Cubist Pharmaceuticals (CBST +5%) to hold from sell (price target raised to $49 from $40) saying concerns about generic competition have abated. Rivkind also notes that investors have plenty of time to wait for "a more attractive entry point," as the next big catalyst for the company is hospital pneumonia data not due until 2015. Comment! [Healthcare, On the Move]
- Monday, May 20, 3:37 PM Cubist Pharmaceuticals (CBST +11.3%) spikes to session highs. The move appears relates to an apparent Markman ruling on Hospira (HSP +0.7%, which has a generic version of Cubist's drug Cubicin. Seeking Alpha contributor PropThink noted last week that the ruling would likely be a 'clearing event' for the company. Comment! [Healthcare, On the Move]
- Wednesday, May 15, 4:01 PM Shares of Optimer Pharmaceutical (OPTR +15%) spike into the close on rumors that Cubist Pharmaceutical (CBST -0.5%) lobbed a $1B bid for OPTR prior to the sales process. Comment! [Healthcare, M&A, On the Move]
- Monday, May 13, 5:09 PM Shares of Optimer Pharmaceutical (OPTR +14%) ramped up into the close on reports that AstraZeneca (AZN), Astellas Pharma (ALPMY.PK) and Cubist Pharmaceuticals (CBST) are among the first round bidders for the antibiotic manufacturer. OPTR disclosed almost three months ago that they were working with Centerview Partners and JPMorgan to explore its strategic options, including a potential sale. Comment! [Healthcare, On the Move, M&A]
- Tuesday, May 7, 9:00 AM Cubist Pharmaceuticals (CBST) pops 2.56% premarket after the FDA grants Fast Track status (again) to the antibiotic CXA-201 which has now received the designation for all of its indications and is being evaluated in Phase 3 clinicals. (PR) Comment! [Healthcare, On the Move]
- Friday, May 3, 11:17 AM Cubist Pharmaceuticals (CBST +3.2%) outperforms after UBS starts coverage with a Buy and $61 PT. Jim Cramer recently gave a shout-out to the drug developer, which ticked higher in April following its Q1 miss. Comment! [Healthcare, On the Move]
- Thursday, April 18, 4:13 PM Cubist Pharma (CBST): Q1 EPS of $0.34 misses by $0.16. Revenue of $229.9M (+9% Y/Y) misses by $13.65M. Shares -0.3% AH. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, April 18, 12:10 AM Notable earnings after Thursday’s close: ACTG, ALGN, AMD, BGS, CBST, CE, CMG, COF, CPHD, ETFC, GOOG, IBM, ISRG, LSCC, MSFT, RMBS, VMI, WIT Comment! [Earnings]
- Wednesday, April 17, 5:35 PM Notable earnings after Thursday’s close: ACTG, ALGN, AMD, BGS, CBST, CE, CMG, COF, CPHD, ETFC, GOOG, IBM, ISRG, LSCC, MSFT, RMBS, VMI, WIT Comment! [Earnings]
- Wednesday, April 3, 11:31 AM Cubist Pharmaceuticals (CBST -3.1%) falls after Cantor Fitzgerald says the company's development of a competing product indicates it likely isn't preparing to bid for Optimer Pharmaceuticals (OPTR +0.1%). Analyst Irina Rivkind downgraded the stock to Sell Wednesday. (See: Optimer surges on takeover chatter) Comment! [Healthcare]
- Tuesday, April 2, 10:02 AM Optimer Pharmaceuticals (OPTR) surges 18.1% following a report that the antibiotics maker has attracted takeover interest from GlaxoSmithKline (GSK), AstraZeneca (AZN), Cubist Pharmaceuticals (CBST) and Japan's Astellas. Optimer hopes to fetch up to $1B in an auction, well above its market cap of $660M. The company has one drug on the market, Dificid, which is used to treat intestinal infections in hospitalized patients. 1 Comment [Healthcare, On the Move]
- Friday, March 15, 1:56 PM Cubist Pharmaceuticals (CBST -1.3%) slips on a less-than-stellar initiation at Credit Suisse with a Neutral rating and a $52 price target. The firm says it expects that positive CXA-201 data in the second half will strengthen confidence in the long-term sustainability of it's antibiotic franchise and be the impetus for global expansion. Comment! [Healthcare, On the Move]
- Thursday, February 28, 5:26 PM Cubist Pharmaceuticals (CBST) says the FDA has designated the company's late-stage antibiotic candidate, ceftolozane/tazobactam, as a Qualified Infectious Disease Product for the indications of Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia and Complicated Urinary Tract Infections. Additionally, the FDA also granted the drugs Fast Track status for Complicated Intra-Abdominal Infections and Clostridium difficile-Associated Diarrhea. Shares +4% AH. Comment! [Healthcare, On the Move]
- Wednesday, February 20, 3:43 PM Nabors Industries' (NBR) weak Q4 should pressure management to take stronger restructuring steps, Goldman's Waqar Syed says; shares are undervalued vs. peers, "a major change for a company that has historically traded at a premium." Of all 67 stocks on Goldman's Conviction Buy list, NBR is one of nine eyed for 30%-plus upside; the others are PANW, AAPL, HAL, TUMI, PRU, F, THOR, CBST. 1 Comment [Energy, Quick Ideas]
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
wallstreetpro2
also look at CBST around $47.75 this thing has been in a huge uptrend for last 3 months today maybe buying opportunity - View all 0 replies
-
- View all 0 replies
-
ZetaKap
3 Mid Cap Stocks Loaded With Cash And Set To Grow http://bit.ly/PLDPXE $BMRN $CBST $KNM @ZetaKap - View all 0 replies
-
- View all 1 replies
-
LATEST REPLIES
-
- View all 1 replies
-
-
- View all 2 replies
-
-